试用视觉搜索
使用图片进行搜索，而不限于文本
你提供的照片可能用于改善必应图片处理服务。
隐私政策
|
使用条款
在此处拖动一张或多张图像或
浏览
在此处放置图像
或
粘贴图像或 URL
拍照
单击示例图片试一试
了解更多
要使用可视化搜索，请在浏览器中启用相机
English
全部
图片
灵感
创建
集合
视频
搜索
地图
资讯
更多
购物
航班
旅游
酒店
笔记本
自动播放所有 GIF
在这里更改自动播放及其他图像设置
自动播放所有 GIF
拨动开关以打开
自动播放 GIF
图片尺寸
全部
小
中
大
特大
至少... *
自定义宽度
x
自定义高度
像素
请为宽度和高度输入一个数字
颜色
全部
仅限颜色
黑白
类型
全部
照片
剪贴画
素描
动画 GIF
透明
版式
全部
方形
横版
竖版
人物
全部
仅脸部
半身像
日期
全部
过去 24 小时
过去一周
过去一个月
去年
授权
全部
所有创作共用
公共领域
免费分享和使用
在商业上免费分享和使用
免费修改、分享和使用
在商业上免费修改、分享和使用
详细了解
清除筛选条件
安全搜索:
中等
严格
中等（默认）
关闭
筛选器
600×776
academia.edu
(PDF) ACR70-disease activity s…
367×362
electronicdissertation.web.fc2.com
acr20
450×338
slideplayer.com
Percentages of (A) ACR 20, 50, and 70 responders, and (B) patie…
1024×768
slideplayer.com
Efficacy end points: the percentage of patients achieving an improve…
450×338
slideplayer.com
Efficacy end points: the percentage of patients achieving an improve…
850×1338
researchgate.net
Proportions of ACR20 (A), A…
320×320
researchgate.net
AR-C17 increases ACar levels in plasma of aging …
850×164
researchgate.net
Proportion of patients achieving (A) 20% improvement in American... | Download Scientific Diagram
850×389
researchgate.net
AR-C17 increases ACar levels in brown adipose tissue (BAT) of aging... | Download Scientific Diagram
320×320
researchgate.net
Clinical efficacy evaluated by ACR/20/50/70. (a) Compariso…
320×320
researchgate.net
Distribution of ACR-1987 criteria, and fulfilment of 5-7 criteria, for…
1024×768
slideplayer.com
ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alo…
1024×768
slideplayer.com
ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 5…
1024×768
slideplayer.com
Highlights From San Francisco ppt download
1024×768
slideplayer.com
Odds ratios for achieving ACR50 response, ACR70 response, DAS2…
640×640
researchgate.net
Univariate analysis of ACR20 response rate by …
850×191
researchgate.net
Proportions of ACR20 (a), ACR50 (b), ACR70 (c), responders in the LTE... | Download Scientific ...
1060×416
article.sapub.org
Clinical Effectiveness of Adalimumab and Methotrexate Combination Therapy in Rhe…
850×435
researchgate.net
Proportion of patients who achieved an ACR 20 and ACR 50 response over... | Downloa…
640×640
researchgate.net
Proportion of patients who achieved an A…
850×220
ResearchGate
Effective rate according to the ACR20, ACR50, and ACR70 | Download Table
320×320
ResearchGate
Effective rate according to the ACR20, ACR50, an…
850×644
researchgate.net
ACR20/50/70 a , HAQ-DI b , and PASI50/75 c response rate (SE) …
850×1601
researchgate.net
Proportion of patients achie…
320×320
researchgate.net
Proportion of patients achieving composite ou…
714×1410
researchgate.net
ACR20, ACR50, and ACR70 re…
850×823
researchgate.net
Proportions of patients
850×855
ResearchGate
Proportion of patients achieving (A) ACR20 resp…
500×418
ascpt.onlinelibrary.wiley.com
Simultaneous Exposure–Response Modeling of ACR20, ACR50, and …
709×391
researchgate.net
ACR70 improvement after 24 weeks of treatment | Download Scientific Diagram
850×679
researchgate.net
Rates over time of ACR20, ACR50, and ACR70, and mean changes in.…
1499×1171
ascpt.onlinelibrary.wiley.com
Simultaneous Exposure–Response Modeling of ACR20, ACR50, and A…
500×361
tandfonline.com
Full article: Sarilumab monotherapy or in combinatio…
1523×523
ascpt.onlinelibrary.wiley.com
Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvemen…
850×497
researchgate.net
ACR20, ACR50, and ACR70 at week 12 (per-protocol set). Significant p... | Do…
某些结果已被隐藏，因为你可能无法访问这些结果。
显示无法访问的结果
报告不当内容
请选择下列任一选项。
无关
低俗内容
成人
儿童性侵犯
反馈
反馈
%2bof%2b(A)%2b20%2525%2b(ACR20)%252C%2b(B)%2b50%2525%2b(ACR50)%2bor%2b(C)%2b70%2525%2b(ACR70)%2bover%2btime%2bthough%2b24%2bweeks%253B%2b(D)%2bmean%2bchange%2bfrom%2bbaseline%2bin%2bClinical%2bDisease%2bActivity%2bIndex%2b(CDAI)%2bover%2btime%253B%2b(E)%2bmean%2bchange%2bfrom%2bbaseline%2bin%2bDisease%2bActivity%2bScore%2bbased%2bon%2b28%2bjoints%2band%2bC%2breactive%2bprotein%2bvalue%2b(DAS28)%2b(CRP)%2bover%2btime%253B%2b(F)%2bmean%2bchange%2bfrom%2bbaseline%2bin%2bHealth%2bAssessment%2bQuestionnaire-Disability%2bIndex%2b(HAQ-DI)%2bover%2btime..jpg&cdnurl=https%3a%2f%2fth.bing.com%2fth%2fid%2fR.1a0ae76c5a4f4d74230f2b0d692959c7%3frik%3dbCK2tJn%252f5ktY%252fQ%26pid%3dImgRaw%26r%3d0&exph=768&expw=1024&q=ACR70+Score&simid=608020787252658170&FORM=IRPRST&ck=FAFAA9005EB5B4377BE3F8AC0E889BA2&selectedIndex=3&itb=0)
%252C%2bACR50%2b(B)%2band%2bACR70%2b(C)%2bare%2bshown..jpg&cdnurl=https%3a%2f%2fth.bing.com%2fth%2fid%2fR.ce8f54405f98a8bab1f034e907526ced%3frik%3d8FHwXF6ILXQMIA%26pid%3dImgRaw%26r%3d0&exph=768&expw=1024&q=ACR70+Score&simid=608035832499219452&FORM=IRPRST&ck=E2D586D706D9C456497B1EEAF878B83C&selectedIndex=11&itb=0)
%2bin%2bpatients%2bwith%2brheumatoid%2barthritis%2brandomised%2bto%2breceive%2bdouble-blind%2bSB5%2b(SB5%2bgroup)%2bor%2breference%2badalimumab%2b(ADL%2boverall%2bgroup)%2bat%2bweek%2b0%252C%2band%2bpatients%2bin%2bthe%2bADL%2bgroup%2bwho%2bwere%2brandomised%2bat%2bweek%2b24%2bto%2bcontinue%2bdouble-blind%2bADL%2b(ADL%2fADL%2bgroup)%2bor%2bswitch%2bto%2bSB5%2b(ADL%2fSB5%2bgroup)%2bup%2bto%2bweek%2b52%2bin%2ba%2bphase%2bIII%2bclinical%2btrial.33%2bACR%252C%2bAmerican%2bCollege%2bof%2bRheumatology%253B%2bADL%252C%2badalimumab..jpg&cdnurl=https%3a%2f%2fth.bing.com%2fth%2fid%2fR.a01bef0e8260fe82f16d43f2935cd86e%3frik%3dappuCNUJcDdcuQ%26pid%3dImgRaw%26r%3d0&exph=768&expw=1024&q=ACR70+Score&simid=608034934862215509&FORM=IRPRST&ck=D4C8B2F7D17C0CBAEA2F33AEDD90C7BF&selectedIndex=12&itb=0)
